Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | Steven KielArquitos Capital Management | Finch Therapeutics $FNCH• NASDAQ | -- | Long FNCH (Finch Therapeutics Group, Inc.) Finch is executing a strategic Chapter 11 filing to shed lease liabilities and execute a full sale of its assets, including valuable patents and major ongoing litigation claims. The manager believes... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Steven KielArquitos Capital Management | Finch Therapeutics $FNCHQ• NASDAQ | -- | Arquitos Capital Management - FNCHQ Finch Therapeutics' court-supervised auction and patent litigation yielded a result at the lower end of expectations. Despite these disappointments... | NEUTRAL | View Pitch → |
| Nov 28, 2025 | Fund Letter | Steven KielArquitos Capital Management | Finch Therapeutics $FNCH• NASDAQ | -- | Arquitos Capital Management 2025 Q3 (FNCH) Finch's share price rose to $12.28 at the end of the third quarter, up from $11.30 at the start of the year. As a reminder,... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.